Registration Dossier

Diss Factsheets

Administrative data

Key value for chemical safety assessment

Toxic effect type:
dose-dependent

Effects on fertility

Description of key information

The no observed adverse effect level (NOAEL) of Reactive Red 245 for maternal toxicity was 50 mg/kg bw and for Reproductive parameters was 1000 mg/kg bw

Link to relevant study records
Reference
Endpoint:
screening for reproductive / developmental toxicity
Type of information:
experimental study
Adequacy of study:
key study
Study period:
2012-11-26 to 2013-09-17
Reliability:
1 (reliable without restriction)
Rationale for reliability incl. deficiencies:
guideline study
Qualifier:
according to guideline
Guideline:
OECD Guideline 421 (Reproduction / Developmental Toxicity Screening Test)
Version / remarks:
27 July 1995
Deviations:
no
Qualifier:
according to guideline
Guideline:
other: Commission Regulation (EC) No. 440/2008, L 142
Version / remarks:
May 30, 2008
Deviations:
no
GLP compliance:
yes (incl. QA statement)
Limit test:
no
Specific details on test material used for the study:
SOURCE OF TEST MATERIAL
- Source and lot/batch No.of test material: BOP 01-12 (Lot: BS-1109708)
- Expiration date of the lot/batch: 06 February 2017

STABILITY AND STORAGE CONDITIONS OF TEST MATERIAL
- Storage condition of test material: at room temperature
Species:
rat
Strain:
Wistar
Details on species / strain selection:
This test is performed on the rat. Although several mammalian species may be used, the rat is the preferred rodent species.
Sex:
male/female
Details on test animals or test system and environmental conditions:
TEST SYSTEM:
Species/strain: Wistar rats, Crl: WI(Han) (Full Barrier)
Source: Charles River, 97633 Sulzfeld, Germany
Sex: male and female; the female animals will be non-pregnant and nulliparous.
Age at the start of the treatment period: males: 10 - 11 weeks old, females: 10 - 11 weeks old.

Body weight at the allocation of the animals to the experimental groups: males: 253 - 296 g (mean: 279.77 g, ± 20% = 223.82 – 335.73 g)
females: 173 - 209 g (Mean: 194.44 g, ± 20% = 155.55 – 233.33 g)
The animals were derived from a controlled full-barrier maintained breeding system (SPF). According to Art. 9.2, No. 7 of the German Act on Animal Welfare the animals were bred for experimental purposes.

HOUSING AND FEEDING CONDITIONS:
- Full barrier in an air-conditioned room
- Temperature: 22 +/- 3 °C
- Relative humidity: 55 +/- 10%
- Artificial light, sequence being 12 h light, 12 h dark
- Air change: 10 x / h
- Free access to Altromin 1324 maintenance diet for rats and mice (Lot. No. 1039)
- Free access to tap water, sulphur acidified to a pH of approximately 2.8 (drinking water, municipal residue control, microbiological controls at regular intervals)
- The animals were housed individually in IVC cages, type III H, polysulphone cages on Altromin saw fibre bedding (Lot. No. 160812) except during mating period when individual male and female rats were cohabited.
- Certificates of food, water and bedding are filed at BSL BIOSERVICE.
- Adequate acclimatisation period (at least five days)
Route of administration:
oral: gavage
Vehicle:
water
Details on exposure:
The test item and vehicle were administered at a single dose to the animals by oral gavage. The dose volume for all groups was 5 mL/kg body weight.
For each animal the individual dosing volume was calculated on the basis of the body weight most recently measured on weekly basis.
Details on mating procedure:
Mating was performed in a ratio of 1:1 (male to female). The vaginal smear of the females was checked every morning after the start of the mating period to confirm the pregnancy. The day of the vaginal plug and/or sperm was considered as day 0 of gestation.
The cages were arranged in such a way that possible effects due to cage placement were minimised.
Analytical verification of doses or concentrations:
yes
Details on analytical verification of doses or concentrations:
Each dosing concentration were analysed with respect to the target nominal concentration. Stability and homogeneity of the test item in the vehicle were analysed for the low and high dose concentrations.
Samples for the nominal concentration verification were taken in study week 1 (first week of pre-mating period), 3 (first week of mating), 5 (gestation) and 7 (gestation/lactation) from all groups (16 samples).
Samples for homogeneity analysis were taken from the top, middle and bottom of the high dose and the low dose formulation in study week 1 and 5 (12 samples).
Samples for stability analysis were taken in the first week of the study, 0 h after the preparation and another sample 6 h after the preparation (at room temperature), from high and low dose formulations (4 samples).
All formulation samples were analysed on same day of sample collection or were stored at -20°C until the analysis was performed.
All samples were analysed at BSL BIOSERVICE Scientific Laboratories GmbH.
Duration of treatment / exposure:
Males: 28 days; Females: approx. 54 days
Frequency of treatment:
7 days/ week
Details on study schedule:
Arrival of the Test Item: 28 September 2012
Study Initiation Date: 26 November 2012
1st Amendment to Study Plan: 27 June 2013
Experimental Starting Date: 04 December 2012
Experimental Completion Date: 27 January 2013
Completion Date of Delegated Phase (Histopathology): 14 August 2013
Completion Date of Delegated Phase (Formulation Analysis): 09 September 2013
Dose / conc.:
0 mg/kg bw/day
Remarks:
Control
Dose / conc.:
50 mg/kg bw/day
Remarks:
Low Dose
Dose / conc.:
250 mg/kg bw/day
Remarks:
Medium Dose
Dose / conc.:
1 000 mg/kg bw/day
Remarks:
High Dose
No. of animals per sex per dose:
10 animals/sex/dose
Control animals:
yes, concurrent vehicle
Details on study design:
Number and sex of the animals
80 animals (40 males and 40 females) were included in the study (10 male and 10 female animals per group).

Preparation of the animals
Prior to the start of the treatment period a detailed clinical observation outside the home cage was made. Before the first administration all animals used for the study were weighed and assigned to the experimental groups with achieving a most homogenous variation in body weight throughout the groups of males and females.

Dosage
In consultation with the sponsor the doses 50, 250, 1000 were selected for the 3 dose groups (LD, MD and HD):
The animals were treated with the test item formulation or vehicle on 7 days per week for a period of minimum 28 days for males and maximum of 54 days for females, i.e. during 14 days of pre-mating and maximum 14 days of mating in both males and females, during the gestation period and up to post-natal day 3 in females.
The highest dose level was chosen with the aim of inducing toxic effects, but no death or severe suffering. Thereafter, a descending sequence of dose levels was selected with a view to demonstrate any dosage related response and NOAEL.
The animals in the control group were handled in an identical manner to the test group subjects and received the vehicle using the same volume as used for the high dose group.

Administration of doses
The test item and vehicle were administered at a single dose to the animals by oral gavage. The application volume for all groups was 5 mL/kg body weight. For each animal the individual dosing volume was calculated on the basis of the body weight most recently measured on weekly basis.

Mating
Mating was performed in a ratio of 1:1 (male to female). The vaginal smear of the females was checked every morning after the start of the mating period to confirm the pregnancy. The day of the vaginal plug and/or sperm was considered as day 0 of gestation.
The cages were arranged in such a way that possible effects due to cage placement were minimised.

Clinical observation
General clinical observations were made at least once a day. The health condition of the animals was recorded. Twice daily all animals were observed for morbidity and mortality except on weekends and public holidays when observations were made once daily.

Body weight and food Consumption
The body weight was recorded once before the assignment to the experimental groups, on the first day of administration and weekly during the treatment period as well as at the end of the study. During pregnancy, females were weighed on gestation days (GD) 0, 7, 14 and 20 and within 24 hours of parturition (day 0 post-partum) as well as day 4 post-partum along with pups. Any animals prematurely sacrificed were weighed prior to the sacrifice.
Food consumption was measured on the corresponding days of the body weight measurements after the beginning of the dose administration. Food consumption was not measured during the mating period in males and females and the post-mating period in males.

Litter observations
The duration of the gestation was recorded and was calculated from day 0 of the pregnancy. Each litter was examined as soon as possible after delivery of the dam to establish the number and sex of pups, stillbirths, live births, runts and the presence of gross abnormalities.
Live pups were counted and sexed and litters weighed within 24 hours of parturition (day 0 post-partum) and on day 4 post-partum. Live pups were identified by tatooing. In addition to the observations of parent animals, any abnormal behaviour of the offspring was recorded.

Pathology
Gross necropsy
All male animals were sacrificed after the completion of the mating period (minimum dosing period: 28 days) on study day 29 or 31, while female animals were sacrificed on post-natal day 4 using an anaesthesia (ketamine/xylazin, 2:1, medistar Arzneimittel, lot no: 00312, expiry date: 06/2014 and Serumwerk, lot no: 00312, expiry date: 05/2014 and lot no: 00512, expiry date: 07/2014) was used. All surviving pups were killed on post natal day 4 by decapitation.
Dead pups and pups sacrificed on day 4 post-partum were carefully examined externally for gross abnormalities.
Non-pregnant females were sacrificed on study day 26 using the sperm-positive vaginal smear as an evidence of mating.
All animals were subjected to a detailed gross necropsy which includes careful examination of the external surface of the body, all orifices and the cranial, thoracic and abdominal cavities and their contents.
Special attention was paid to the organs of the reproductive system. The ovaries, uterus with cervix, vagina, testes, epididymides, accessory sex organs (prostate, seminal vesicles with coagulating glands as a whole), and all organs showing macroscopic lesions of all adult animals were preserved in 10 % neutral buffered formalin, except for testes and epididymides which were fixed in modified Davidson’s Solution for 24 hours and then transferred in 10 % neutral buffered formalin.
The number of implantation sites and corpora lutea was recorded for each parental female at necropsy.

Organ weight
The testes and epididymides of all male adult animals as well as the ovaries, uterus with cervix of all female adult animals were weighed.
Paired organs were weighed separately.

Histopathology
Testes, epididymides, ovaries, uterus with cervix, vagina, accessory sex organs (prostate, seminal vesicle with coagulating gland) and all organs showing gross lesions were examined in C and HD animals. Macroscopic changes were evaluated in all study animals.
For the testes, a detailed qualitative examination was made; taking into account the tubular stages of the spermatogenic cycle at evaluation of additional hematoxylin-PAS (Periodic Acid Schiff) stained slides.
The histological processing of tissues to microscope slides was performed at the GLP-certified contract laboratory Propath UK Ltd, Willow Court, Netherwood Road, Hereford HR2 6JU, Great Britain (test site for tissue processing). The histopathological evaluation was performed at the GLP-certified contract laboratory KALEIDIS – Consultancy in Histopathology (test site for histopathology), 6 rue du Gers, 68300 Saint-Louis, France. Blocking, embedding, cutting, H&E staining and scientific slide evaluation was performed according to the corresponding SOP’s of the test sites.
Parental animals: Observations and examinations:
Body weight, food consumption, clinical signs, pathology, organ weight (reproductive organs), histopathology (reproductive organs)

CAGE SIDE OBSERVATIONS: Yes
- Time schedule: Once a day (except weekends and public holidays)


DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: General clinical observations were made at least once a day. The health condition of the animals was recorded. Twice daily all animals were observed for morbidity and mortality except on weekends and public holidays when observations were made once daily.

BODY WEIGHT: Yes
- Time schedule for examinations: The body weight was recorded once before the assignment to the experimental groups, on the first day of administration and weekly during the treatment period as well as at the end of the study. During pregnancy, females were weighed on gestation days (GD) 0, 7, 14 and 20 and within 24 hours of parturition (day 0 post-partum) as well as day 4 post-partum along with pups.

Oestrous cyclicity (parental animals):
Not examined
Sperm parameters (parental animals):
Not examined
Litter observations:
The duration of gestation was recorded and was calculated from day 0 of pregnancy. Each litter was examined as soon as possible after delivery of the dam to establish the number and sex of pups, stillbirths, live births, runts and the presence of gross abnormalities.

Live pups were counted and sexed. Litters were weighed within 24 hours of parturition (day 0 post-partum) and on day 4 post-partum. Live pups were identified by marking with tattoo. In addition to the observations on parent animals, any abnormal behavior of the offspring was recorded.
Postmortem examinations (parental animals):
yes
Postmortem examinations (offspring):
not examined
Statistics:
For statistical analysis one-way analysis of variance (ANOVA) followed by Dunnett’s multiple comparison test was carried out to reveal any differences between control- and test groups. Statistical analysis was performed with GraphPad Prism (version V) software and p<0.05 was considered as statistical significant.
Reproductive indices:
Copulation, fertility, delivery indices
Offspring viability indices:
yes
Clinical signs:
effects observed, non-treatment-related
Description (incidence and severity):
There were clinical signs namely reddish nasal discharge, hematoma (ear), piloerection, alopecia, salivation, abnormal breathing, respiratory sound and moving the bedding seen transiently in most animals of treated groups when compared to controls. As the clinical signs were seen transiently, the findings were not considered to be an adverse effect.
Mortality:
no mortality observed
Description (incidence):
However, one animal (No. 70) was euthanized as the animal had consumed the gavaging cannula and as a result the general health condition of the animal was deteriorated.
Body weight and weight changes:
no effects observed
Description (incidence and severity):
In males and females, there were no effects on body weight and body weight change throughout the study period in treated groups when compared with controls. The statistical analysis of data revealed no significant changes between the treated and control groups. However, there was decrease in body weight change in male HD group on 1st week of premating without attaining the statistical significance. This was due to one single male animal (Animal No. 39) which did not show weight gain during the first week, but during the later days gained the weight that was within the range of variations.
Food consumption and compound intake (if feeding study):
no effects observed
Description (incidence and severity):
In males and female, there was no effect on food consumption during the study period. The statistical analysis of data revealed no significant changes between the treated and control groups.
Food efficiency:
no effects observed
Water consumption and compound intake (if drinking water study):
not examined
Ophthalmological findings:
not examined
Haematological findings:
not examined
Clinical biochemistry findings:
not examined
Urinalysis findings:
not examined
Behaviour (functional findings):
not examined
Immunological findings:
not examined
Organ weight findings including organ / body weight ratios:
no effects observed
Histopathological findings: non-neoplastic:
effects observed, treatment-related
Description (incidence and severity):
Histologically, in HD group, minor degrees of red-brown pigment in interstitial macrophages were seen in the epididymis and/or testis of all and in the prostate gland of one single male rat. In MD group, red-brown pigment was noted in the testis of one single male. These changes were considered to represent test item deposition in macrophages. No test item-related histological findings were noted in the other male and in the female reproductive organs. One control female and one female of MD group did not show any indication of recent pregnancy at necropsy. As there was no dose relationship, this was considered to be unrelated to treatment. In the kidney, minor amounts of red pigment were observed in the corticotubular epithelium, in the majority of animals of HD group, and in one male and one female of MD group. This change was considered to be caused by deposition of the coloured test item. In addition, in MD and HD groups, minimal to moderate numbers of corticoepithelial hyaline droplets were noted in the males, and minimal to moderate corticotubular degeneration/regeneration was seen, predominantly in the females. These findings were considered to be related to test item administration and to be adverse. Furthermore, in HD group only, minor sinus histiocytosis, partially red pigmented, was seen in the mesenteric lymph node and mandibular lymph node, and minimal numbers of red-pigmented histiocytes were noted in small intestinal villi of one single male. Lymph node and intestinal changes were considered to represent test item deposition in macrophages.
Other effects:
not specified
Reproductive function: oestrous cycle:
not examined
Reproductive function: sperm measures:
not examined
Reproductive performance:
no effects observed
Day of sacrifice
Except one animal in MD group (animals 70) all other animals in treated and control groups survived the treatment period. The animal (no. 70) had consumed the gavaging cannula due to which the general health condition of the animal was deteriorated. The animal was euthanized on Gestation Day 15.
Dose descriptor:
NOAEL
Remarks:
Reproduction toxicity
Effect level:
1 000 mg/kg bw/day
Based on:
test mat.
Sex:
male/female
Basis for effect level:
other: No findings of toxicological relevance were observed up to the highest dose tested.
Dose descriptor:
NOAEL
Remarks:
Systemic toxicity
Effect level:
50 mg/kg bw/day
Based on:
test mat.
Sex:
male/female
Basis for effect level:
histopathology: non-neoplastic
Critical effects observed:
yes
Lowest effective dose / conc.:
250 mg/kg bw/day (nominal)
System:
other: urinary and male reproductive sytem
Organ:
kidney
lymph node
testes
Treatment related:
yes
Dose response relationship:
not specified
Relevant for humans:
not specified
Description (incidence and severity):
No mortality observed.
Sexual maturation:
not examined
Anogenital distance (AGD):
no effects observed
Organ weight findings including organ / body weight ratios:
not examined
Gross pathological findings:
not examined
Histopathological findings:
not examined
Other effects:
no effects observed
Dose descriptor:
NOAEL
Generation:
F1
Effect level:
1 000 mg/kg bw/day (nominal)
Based on:
test mat.
Sex:
male/female
Remarks on result:
not determinable due to absence of adverse toxic effects
Critical effects observed:
no
Reproductive effects observed:
no
Conclusions:
The No Observed Adverse Effect Level (NOAEL) of FAT 40348/F TE for systemic toxicity is considered to be 50 mg/kg body weight and 1000 mg/kg body weight for reproduction toxicity respectively.
Executive summary:

A reproduction/ developmental toxicity screening test was conducted to assess the possible effects of FAT 40348/F TE as per OECD 421 guideline after repeated administration in Wistar rats on male and female fertility and embryo-fetal development.

The test item was administered daily in graduated doses to 3 groups of test animals, one dose level per group for a minimum treatment period of 28 days for males and a maximum treatment period of 54 days for females, i.e. during 14 days of pre-mating and maximum 14 days of mating in both males and females, during the gestation period and up to post-natal day 3 in females. Animals of control group were handled identically as the dose groups but received the vehicle. The 4 groups comprised 10 male and 10 female Wistar rats.

During the period of administration, the animals were observed each day for signs of toxicity. Body weight and food consumption were measured weekly, except for food consumption measurements which were not taken during the mating period in female animals and the mating and post-mating period in male animals.

After 14 days of treatment animals were mated (1:1) for a maximum of 14 days. The subsequent morning onwards the vaginal smears of females were checked to confirm the evidence of mating. After the confirmation of the mating, females were separated and housed individually.

The males were sacrificed after completion of the mating period on days 29 and 31 and the females along with their pups were sacrificed on post natal day 4. Non-pregnant females were sacrificed on day 26 from the day of confirmed mating.

The number of implantation sites and corpora lutea was recorded for each parental female at necropsy.

The testes and epididymides of all male adult animals as well as the ovaries, uterus with cervix of all female adult animals were weighed. Paired organs were weighed separately. Testes, epididymides, ovaries, uterus with cervix, vagina and accessory sex organs (prostate, seminal vesicle with coagulating gland) were examined in C and HD animals. Macroscopic changes were evaluated in all study animals.

  

The following doses were evaluated:

Control:                          0        mg/kg body weight

Low Dose:                     50       mg/kg body weight

Medium Dose:              250     mg/kg body weight

High Dose:                   1000   mg/kg body weight

The test item formulation was prepared freshly on each day of administration. The test item was dissolved in aqua ad injectionem and administered daily during 14 days of pre-mating and 14 days of mating in both male and female animals, during the gestation period and up to post-natal day 3 in females. Males were dosed for a minimum dosing period of 28 days (half males of each group were treated 28 days and rest half males treated for 30 days). Dose volumes were adjusted individually based on weekly body weight measurements.Theadministration volume was 5 mL/kg body weight.

Summary Results

There was no mortality caused due to treatment. However, one animal (No. 70) was euthanized as the animal had consumed the gavaging cannula and as a result the general health condition of the animal was deteriorated.

There were clinical signs namely reddish nasal discharge, hematoma (ear), piloerection, alopecia, salivation, abnormal breathing, respiratory sound and moving the bedding seen transiently in most animals of treated groups when compared to controls. As the clinical signs were seen transiently, the findings were not considered to be an adverse effect.

In males and females, there were no effects on body weight, body weight change and food consumption noted throughout the study period in treated groups when compared with controls.

There were no treatment related changes noted on group mean litter weight, total litter weight, male litter weight and female litter weight measured on PND 0 and PND 4.

There were no treatment related effect observed on the duration of gestation and precoital interval in the treated groups when compared with controls.

All females in control and treated groups showed evidence of copulation during 14 days mating period. Successful mating of females resulted in pregnancy rate as follows, Control 90%, LD group 100% MD group 90% and HD group 100%.

One control female (No. 48) and one female of MD group (No. 67) did not show any indication of recent pregnancy at terminal sacrifice. There was no dose relationship, and this was therefore considered to be unrelated to treatment.

There were no treatment related changes noted for group means of corpora lutea, implantation sites and live pups born on PND 0 in the treated groups when compared with corresponding controls. The mean values of percent pre and post implantation loss was higher in HD group, but these findings were not related to adverse effect due to treatment.

The copulation index, fertility index and viability index remained unaffected due to treatment in treated groups compared to corresponding control.

All pregnancies except one isolated female in HD (animal 77) groups resulted in normal births. Considering the absence of overt clinical signs during the treatment period and also absence of any structural impairment of reproductive organs the above finding was not related to an adverse effect due to treatment.

Red or reddish discoloration of a number of organs was observed in all animals of HD group. Organs concerned were one or several of the following: male and female reproductive organs, kidney, mesenteric lymph node, axillary lymph node, mandibular lymph node, skin, adrenal gland, thymus and gastrointestinal tract. In MD group, kidney, mesenteric lymph node and/or testis/epididymis were found to be red or reddish discolored in a proportion of animals, predominantly in the males. These color changes were considered to be caused by the color of the test item itself.

Other macroscopic organ findings were very few and not considered to be test item-related, including proliferating tissue at the kidney of one male of LD group.

In males and females, the organ weight data (absolute and relative to terminal body weight) showed no changes considered to be of toxicological relevance.

 

Histologically, in HD group, minor degrees of red-brown pigment in interstitial macrophages were seen in the epididymis and/or testis of all and in the prostate gland of one single male rat. In MD group, red-brown pigment was noted in the testis of one single male. These changes were considered to represent test item deposition in macrophages. No test item-related histological findings were noted in the other male and in the female reproductive organs. One control female and one female of MD group did not show any indication of recent pregnancy at necropsy. As there was no dose relationship, this was considered to be unrelated to treatment. In the kidney, minor amounts of red pigment were observed in the corticotubular epithelium, in the majority of animals of HD group, and in one male and one female of MD group. This change was considered to be caused by deposition of the coloured test item. In addition, in MD and HD groups, minimal to moderate numbers of corticoepithelial hyaline droplets were noted in the males, and minimal to moderate corticotubular degeneration/regeneration was seen, predominantly in the females. These findings were considered to be related to test item administration and to be adverse. Furthermore, in HD group only, minor sinus histiocytosis, partially red pigmented, was seen in the mesenteric lymph node and mandibular lymph node, and minimal numbers of red-pigmented histiocytes were noted in small intestinal villi of one single male. Lymph node and intestinal changes were considered to represent test item deposition in macrophages.

No test item-related histopathological lesions were noted in the other miscellaneous organs evaluated in this study.

Concentration analysis of formulation samples was determined in study week 1, 3, 5 and 7 for all dose groups. The mean recoveries observed in LD, MD and HD groups were 97.3%, 100.1% and 98.6% of the nominal concentration, respectively.

Stability of formulation samples was investigated in study week 1 for LD and HD dose groups. After 6 hours storage at room temperature recovery compared to starting value was 100.7% and 100.7%.

Homogeneity of formulation samples was determined in study week 1 and 5 for LD and HD dose groups. The mean recovery observed for LD dose group was 99.4 and 94.1% of the nominal value and 97.3 and 103.8% for HD dose group.

The coefficients of variation of the different sampling locations (top, middle, bottom) were 0.7 and 6.2% in LD dose group, and 4.1 and 1.0% in HD dose group.

Based on the data generated from this reproduction/ developmental toxicity screening test with FAT 40348/F TE, the no observed adverse effect  level (NOAEL) for systemic toxicity is considered to be 50 mg/kg body weight and 1000 mg/kg body weight for reproduction toxicity respectively.

Effect on fertility: via oral route
Endpoint conclusion:
no adverse effect observed
Dose descriptor:
NOAEL
1 000 mg/kg bw/day
Study duration:
subacute
Species:
rat
Quality of whole database:
GLP compliant guideline study, klimisch 1
Effect on fertility: via inhalation route
Endpoint conclusion:
no study available
Effect on fertility: via dermal route
Endpoint conclusion:
no study available
Additional information

No studies on the reproduction/developmental toxicity of FAT40406 were available. However, Article 13 of REACH states that, in case no appropriate animal studies are available for assessment, information should be generated whenever possible by means other than vertebrate animal tests, i.e. applying alternative methods such as in vitro tests, QSARs, grouping and read-across. One reproduction/developmental toxicity screening test is available for the structural analogue FAT 40348.

The reproduction/ developmental toxicity screening test was conducted to assess the possible effects of FAT 40348/F TE after repeated administration in Wistar rats on male and female fertility and embryo-fetal development.

The test item was administered daily in graduated doses to 3 groups of test animals, one dose level per group for a minimum treatment period of 28 days for males and a maximum treatment period of 54 days for females, i.e. during 14 days of pre-mating and maximum 14 days of mating in both males and females, during the gestation period and up to post-natal day 3 in females.

The following doses were evaluated:

Control:                          0        mg/kg body weight

Low Dose:                     50       mg/kg body weight

Medium Dose:              250     mg/kg body weight

High Dose:                   1000   mg/kg body weight

 

Based on the data generated from this reproduction/ developmental toxicity screening test with FAT 40348/F TE, the no observed adverse effect level (NOAEL) for systemic toxicity is considered to be 50 mg/kg body weight and 1000 mg/kg body weight for reproduction/ developmental toxicity respectively. Treatment related effects for systemic toxicity were seen in reproductive organs, kidney, mesenteric lymph node, axillary lymph node, mandibular lymph node, skin, adrenal gland, thymus and gastrointestinal tract.

Effects on developmental toxicity

Effect on developmental toxicity: via oral route
Endpoint conclusion:
no adverse effect observed
Dose descriptor:
NOAEL
1 000 mg/kg bw/day
Study duration:
subacute
Species:
rat
Quality of whole database:
High quality GLP study
Effect on developmental toxicity: via inhalation route
Endpoint conclusion:
no study available
Effect on developmental toxicity: via dermal route
Endpoint conclusion:
no study available

Justification for classification or non-classification

Based on the absence of adverse effect on reproductive organs or tissues in the reproduction/developmental toxicity screening test, classification is not necessary for toxicity to fertility in accordance with EU Classification, Labeling and Packaging of Substances and Mixtures (CLP) Regulation (EC) No. 1272/2008.

Additional information

Categories Display